Drug Trial Radar · NCT04023552
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8,323
Actual
Start
Dec 12, 2019
Primary completion
Jul 16, 2026
Study completion Jul 16, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 17, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)
Conditions
- Cardiovascular Disease and Lipoprotein(a)
Interventions
TQJ230Drug
TQJ230 80 mg injected monthly administered subcutaneously
PlaceboDrug
Placebo to match TQJ230 prefilled syringe to be injected subcutaneously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first occurrence of clinical endpoint committee confirmed expanded major adverse cardiovascular events in patients with elevated Lp(a) ≥ 70 mg/dLTime frame: approximately 4 years
- Time to the first occurrence of clinical endpoint committee confirmed expanded major adverse cardiovascular events in a population of patients with elevated Lp(a) ≥ 90 mg/dL.Time frame: approximately 4 years
Locations
902 sites in 43 countries. Site status is shown where the registry gives one.
SEC Clinical Research LLC
Andalusia, Alabama
Grandview Med Group Research LLC
Birmingham, Alabama
Novartis Investigative Site
Birmingham, Alabama
Heart Center Research Llc
Huntsville, Alabama
Novartis Investigative Site
Huntsville, Alabama
Mobile Heart Specialists
Mobile, Alabama
Novartis Investigative Site
Mobile, Alabama
Novartis Investigative Site
Cottonwood, Arizona
Mercy Gilbert Medical Center
Gilbert, Arizona
Clinical Research Inst of Arizona
Sun City West, Arizona
Novartis Investigative Site
Sun City West, Arizona
Eclipse Clinical Research
Tucson, Arizona
Novartis Investigative Site
Tucson, Arizona
Cardiology and Medicine Clinic PA
Little Rock, Arkansas
Novartis Investigative Site
Little Rock, Arkansas
Cardiovascular Res Found
Beverly Hills, California
National Heart Institute
Beverly Hills, California
Novartis Investigative Site
Beverly Hills, California
Flourish Clinical Resrch Covin
Covina, California
Novartis Investigative Site
Covina, California
Diabetes Lipid Management Center
Huntington Beach, California
Novartis Investigative Site
Huntington Beach, California
University of Calif Irvine Med Cntr
Irvine, California
Novartis Investigative Site
La Jolla, California
Memorial Care Health System
Long Beach, California
Novartis Investigative Site
Long Beach, California
Keck Medical Center USC
Los Angeles, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Northridge, California
Valley Clinical Trials
Northridge, California
Novartis Investigative Site
Orange, California
Stanford University Medical Center
Palo Alto, California
University of California San Diego
San Diego, California
UCSF
San Francisco, California
Novartis Investigative Site
San Francisco, California
Helping Hands Medical Associates INC
Santa Ana, California
Novartis Investigative Site
Santa Ana, California
Novartis Investigative Site
Stanford, California
Manshadi Heart Institute
Stockton, California
Showing 40 of 902 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.